Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLIS TechnologiesNZSE:BLT +4.55% EV-to-EBITDA is 16.00 as of Aug. 31, 2026, which is 110% above its 10-year median of 7.62. The stock has 8 warning signs investors should review. Among 401 Biotechnology companies, BLIS Technologies ranks worse than 52.62% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BLIS Technologies's enterprise value is NZ$20.08 Mil.
BLIS Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$1.26 Mil. Therefore, BLIS Technologies's EV-to-EBITDA for today is 16.00.
The historical rank and industry rank for BLIS Technologies's EV-to-EBITDA or its related term are showing as below:
NZSE:BLT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1168.99 Med: 7.62 Max: 83.37
Current: 16
During the past 13 years, the highest EV-to-EBITDA of BLIS Technologies was 83.37. The lowest was -1168.99. And the median was 7.62.
NZSE:BLT's EV-to-EBITDA is ranked worse than 52.62% of 401
companies
in the Biotechnology industry
Industry Median: 14.15
vs NZSE:BLT: 16.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BLIS Technologies's PE Ratio (TTM) for today is calculated as:
BLIS Technologies's share price for today is NZ$0.023.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLIS Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BLIS Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, BLIS Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's EV-to-EBITDA falls into.
BLIS Technologies's current Enterprise Value is NZ$20.08 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLIS Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$1.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLIS Technologies (NZSE:BLT) has a EV-to-EBITDA of 16.00 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BLIS Technologies. This is 110% above median its historical median of 7.62. According to the industry distribution chart, BLIS Technologies ranks #211 out of 401 companies in the Biotechnology industry, placing it in the top 52.6%.
Is BLIS Technologies' EV-to-EBITDA too high?
BLIS Technologies' current EV-to-EBITDA of 16.00 is 110% above median its 10-year median of 7.62. The Biotechnology industry median EV-to-EBITDA is 14.15. BLIS Technologies' value of 16.00 is 13.1% above this industry median. Based on the distribution chart, BLIS Technologies ranks #211 out of 401 companies in the Biotechnology industry, which is below the industry midpoint.
How does BLIS Technologies' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #211 out of 401 companies for EV-to-EBITDA. This places BLIS Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 14.15. BLIS Technologies' value of 16.00 is 13.1% above this benchmark. While the company's 10-year median is 7.62 vs. the industry median of 14.15, BLIS Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.15, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLIS Technologies's current EV-to-EBITDA of 16.00 is 13.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BLIS Technologies. For the Biotechnology industry, the median EV-to-EBITDA is 14.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLIS Technologies's current EV-to-EBITDA is 16.00, which is 110% above median its own 10-year median of 7.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Overvalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 15% above its estimated fair value. The current EV-to-EBITDA is 16.00, which is 110% above median its 10-year median of 7.62 and 13.1% above the Biotechnology industry median of 14.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current EV-to-EBITDA is 16.00 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 
